Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 3, 2014, Pages 589-596

  Runchey, Shauna S ^a   Boyko, Edward J ^b   Ioannou, George N ^a   Utzschneider, Kristina M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Fatty liver; Insulin like growth factor binding protein 3; Insulin like growth factor I; National health and nutrition examination survey

Indexed keywords

FAT; INSULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BODY MASS; DISEASE SEVERITY; ECHOGRAPHY; ETHNICITY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNITED STATES; WAIST CIRCUMFERENCE;

ADIPOSITY; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84897648027     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12437     Document Type: Article

References (38)

1. Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005; 128: 627-635.
2. Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K, Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 2003; 52: 914.
3. Takahashi Y, Iida K, Takahashi K etal. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 2007; 132: 938-943.
4. Nishizawa H, Iguchi G, Murawaki A etal. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur. J. Endocrinol. 2012; 167: 67-74.
5. Arturi F, Succurro E, Procopio C etal. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J. Clin. Endocrinol. Metab. 2011; 96: E1640-1644.
6. Colak Y, Senates E, Ozturk O etal. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur. J. Gastroenterol. Hepatol. 2012; 24: 255-261.
7. Garcia-Galiano D, Sanchez-Garrido MA, Espejo I etal. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes. Surg. 2007; 17: 493-503.
8. Volzke H, Nauck M, Rettig R etal. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur. J. Endocrinol. 2009; 161: 705-713.
9. Mallea-Gil MS, Ballarino MC, Spiraquis A etal. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome. Acta Gastroenterol. Latinoam. 2012; 42: 20-26.
10. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 1989; 10: 68-91.
11. Nishizawa H, Takahashi M, Fukuoka H, Iguchi G, Kitazawa R, Takahashi Y. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochem. Biophys. Res. Commun. 2012; 423: 295-300.
12. Bonefeld K, Moller S. Insulin-like growth factor-I and the liver. Liver Int. 2011; 31: 911-919.
13. Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J. Clin. Invest. 1988; 81: 976-981.
14. Ichikawa T, Nakao K, Hamasaki K etal. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol. Int. 2007; 1: 287-294.
15. Okan A, Comlekci A, Akpinar H etal. Serum concentrations of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in patients with chronic hepatitis. Scand. J. Gastroenterol. 2000; 35: 1212-1215.
16. Colakoglu O, Taskiran B, Colakoglu G, Kizildag S, Ari Ozcan F, Unsal B. Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. Turk. J. Gastroenterol. 2007; 18: 245-249.
17. Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A. Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology 2003; 50: 814-816.
18. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2006; 91: 4753-4761.
19. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr. Rev. 1997; 18: 801-831.
20. Plan and operation of the Thirth National Health and Nutrition Examination Survey, 1988-1994. Vital and health statistics 1994. Vol Publication No (PHS) 94-1308: National Center for Health Statistics, Department of Health and Human Services; 1994.
21. Gunter EW, McQuillan G. Quality control in planning and operating the laboratory component for the Third National Health and Nutrition Examination Survey. J. Nutr. 1990; 120 (Suppl. 11): 1451-1454.
22. Berrigan D, Potischman N, Dodd KW etal. Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 1017-1022.
23. Lazo M, Hernaez R, Bonekamp S etal. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343: d6891.
24. Third National Health and Nutrition Examination Survey: Gallbladder Ultrasonography Procedure Manual. September 1988. Cited 3 December 2013. Available from URL: http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/gallblad.pdf
25. Third National Health and Nutrition Examination Survey: Hepatic Steatosis Assessment Procedure Manual. November 2010. Cited 3 December 2013. Available from URL: http://www.cdc.gov/nchs/data/nhanes/nhanes3/Hepatic_Steatosis_Ultrasound_Procedures_Manual.pdf
26. Rudenski AS, Matthews DR, Levy JC, Turner RC. Understanding "insulin resistance": both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 1991; 40: 908-917.
27. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 1): S62-69.
28. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 2009; 30: 152-177.
29. Krusenstjerna-Hafstrom T, Clasen BF, Moller N etal. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. J. Clin. Endocrinol. Metab. 2011; 96: 2548-2557.
30. Amato G, Mazziotti G, Di Somma C etal. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections. J. Clin. Endocrinol. Metab. 2000; 85: 3720-3725.
31. Takahashi Y. Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver. Endocr. J. 2012; 59: 955-962.
32. Ahmed RL, Thomas W, Schmitz KH. Interactions between insulin, body fat, and insulin-like growth factor axis proteins. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 593-597.
33. Hassouna R, Zizzari P, Tolle V. The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake. J. Neuroendocrinol. 2010; 22: 793-804.
34. Parekh N, Roberts CB, Vadiveloo M, Puvananayagam T, Albu JB, Lu-Yao GL. Lifestyle, anthropometric, and obesity-related physiologic determinants of insulin-like growth factor-1 in the Third National Health and Nutrition Examination Survey (1988-1994). Ann. Epidemiol. 2010; 20: 182-193.
35. Lam CS, Chen MH, Lacey SM etal. Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Arterioscler. Thromb. Vasc. Biol. 2010; 30: 1479-1484.
36. Rowlands MA, Holly JM, Gunnell D etal. The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes Control 2010; 21: 1829-1842.
37. Faupel-Badger JM, Berrigan D, Ballard-Barbash R, Potischman N. Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels by race/ethnicity and gender. Ann. Epidemiol. 2009; 19: 841-849.
38. Tobari M, Hashimoto E, Yatsuji S, Torii N, Shiratori K. Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Intern. Med. 2009; 48: 739-746.